Cargando…

Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis

Liver fibrosis is a sign of non-alcoholic fatty liver disease progression towards steatohepatitis (NASH) and cirrhosis and is accelerated by aging. Glutaredoxin-1 (Glrx) controls redox signaling by reversing protein S-glutathionylation, induced by oxidative stress, and its deletion causes fatty live...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsukahara, Yuko, Ferran, Beatriz, Minetti, Erika T., Chong, Brian S. H., Gower, Adam C., Bachschmid, Markus M., Matsui, Reiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138033/
https://www.ncbi.nlm.nih.gov/pubmed/35624731
http://dx.doi.org/10.3390/antiox11050867
_version_ 1784714526387601408
author Tsukahara, Yuko
Ferran, Beatriz
Minetti, Erika T.
Chong, Brian S. H.
Gower, Adam C.
Bachschmid, Markus M.
Matsui, Reiko
author_facet Tsukahara, Yuko
Ferran, Beatriz
Minetti, Erika T.
Chong, Brian S. H.
Gower, Adam C.
Bachschmid, Markus M.
Matsui, Reiko
author_sort Tsukahara, Yuko
collection PubMed
description Liver fibrosis is a sign of non-alcoholic fatty liver disease progression towards steatohepatitis (NASH) and cirrhosis and is accelerated by aging. Glutaredoxin-1 (Glrx) controls redox signaling by reversing protein S-glutathionylation, induced by oxidative stress, and its deletion causes fatty liver in mice. Although Glrx regulates various pathways, including metabolism and apoptosis, the impact of Glrx on liver fibrosis has not been studied. Therefore, we evaluated the role of Glrx in liver fibrosis induced by aging or by a high-fat, high-fructose diet. We found that: (1) upregulation of Glrx expression level inhibits age-induced hepatic apoptosis and liver fibrosis. In vitro studies indicate that Glrx regulates Fas-induced apoptosis in hepatocytes; (2) diet-induced NASH leads to reduced expression of Glrx and higher levels of S-glutathionylated proteins in the liver. In the NASH model, hepatocyte-specific adeno-associated virus-mediated Glrx overexpression (AAV-Hep-Glrx) suppresses fibrosis and apoptosis and improves liver function; (3) AAV-Hep-Glrx significantly inhibits transcription of Zbtb16 and negatively regulates immune pathways in the NASH liver. In conclusion, the upregulation of Glrx is a potential therapeutic for the reversal of NASH progression by attenuating inflammatory and fibrotic processes.
format Online
Article
Text
id pubmed-9138033
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91380332022-05-28 Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis Tsukahara, Yuko Ferran, Beatriz Minetti, Erika T. Chong, Brian S. H. Gower, Adam C. Bachschmid, Markus M. Matsui, Reiko Antioxidants (Basel) Article Liver fibrosis is a sign of non-alcoholic fatty liver disease progression towards steatohepatitis (NASH) and cirrhosis and is accelerated by aging. Glutaredoxin-1 (Glrx) controls redox signaling by reversing protein S-glutathionylation, induced by oxidative stress, and its deletion causes fatty liver in mice. Although Glrx regulates various pathways, including metabolism and apoptosis, the impact of Glrx on liver fibrosis has not been studied. Therefore, we evaluated the role of Glrx in liver fibrosis induced by aging or by a high-fat, high-fructose diet. We found that: (1) upregulation of Glrx expression level inhibits age-induced hepatic apoptosis and liver fibrosis. In vitro studies indicate that Glrx regulates Fas-induced apoptosis in hepatocytes; (2) diet-induced NASH leads to reduced expression of Glrx and higher levels of S-glutathionylated proteins in the liver. In the NASH model, hepatocyte-specific adeno-associated virus-mediated Glrx overexpression (AAV-Hep-Glrx) suppresses fibrosis and apoptosis and improves liver function; (3) AAV-Hep-Glrx significantly inhibits transcription of Zbtb16 and negatively regulates immune pathways in the NASH liver. In conclusion, the upregulation of Glrx is a potential therapeutic for the reversal of NASH progression by attenuating inflammatory and fibrotic processes. MDPI 2022-04-28 /pmc/articles/PMC9138033/ /pubmed/35624731 http://dx.doi.org/10.3390/antiox11050867 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tsukahara, Yuko
Ferran, Beatriz
Minetti, Erika T.
Chong, Brian S. H.
Gower, Adam C.
Bachschmid, Markus M.
Matsui, Reiko
Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis
title Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis
title_full Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis
title_fullStr Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis
title_full_unstemmed Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis
title_short Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis
title_sort administration of glutaredoxin-1 attenuates liver fibrosis caused by aging and non-alcoholic steatohepatitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138033/
https://www.ncbi.nlm.nih.gov/pubmed/35624731
http://dx.doi.org/10.3390/antiox11050867
work_keys_str_mv AT tsukaharayuko administrationofglutaredoxin1attenuatesliverfibrosiscausedbyagingandnonalcoholicsteatohepatitis
AT ferranbeatriz administrationofglutaredoxin1attenuatesliverfibrosiscausedbyagingandnonalcoholicsteatohepatitis
AT minettierikat administrationofglutaredoxin1attenuatesliverfibrosiscausedbyagingandnonalcoholicsteatohepatitis
AT chongbriansh administrationofglutaredoxin1attenuatesliverfibrosiscausedbyagingandnonalcoholicsteatohepatitis
AT goweradamc administrationofglutaredoxin1attenuatesliverfibrosiscausedbyagingandnonalcoholicsteatohepatitis
AT bachschmidmarkusm administrationofglutaredoxin1attenuatesliverfibrosiscausedbyagingandnonalcoholicsteatohepatitis
AT matsuireiko administrationofglutaredoxin1attenuatesliverfibrosiscausedbyagingandnonalcoholicsteatohepatitis